Pembrolizumab-induced lichenoid dermatitis treated with dupilumab.

Park, Jonathan J; Park, Eunsuh; Damsky, William E; Vesely, Matthew D

Park, Jonathan J; Park, Eunsuh; Damsky, William E; Vesely, Matthew D.

Afiliação

Park JJ; Department of Genetics, Yale School of Medicine, New Haven, Connecticut.
Park E; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Damsky WE; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Vesely MD; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.

JAAD Case Rep ; 37: 13-15, 2023 Jul.

Article em En | MEDLINE | ID: mdl-37332364

Palavras-chave

PD-1; cancer immunotherapy; cutaneous immune related adverse events; dupilumab; immune checkpoint; lichen planus; lichenoid dermatitis; pembrolizumab; programmed death 1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google